clinical trial · NCT00388882
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
Boehringer Ingelheim·phase4·completed·n = 327
Pulmonary Disease, Chronic Obstructivetiotropiumipratropium bromide / albuterol
brief summary
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler® 18 mcg daily compared to Combivent® MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently prescribed Combivent® MDI.
started
Oct 4, 2006
primary completion
Oct 8, 2007
completion
—
last updated
Dec 1, 2023
official title
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol